Soleno Therapeutics (SLNO) Operating Income: 2013-2017
Historic Operating Income for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$5.2 million.
- Soleno Therapeutics' Operating Income fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.49%. This contributed to the annual value of -$187.7 million for FY2024, which is 353.49% down from last year.
- As of Q4 2017, Soleno Therapeutics' Operating Income stood at -$5.2 million, which was down 97.61% from -$2.6 million recorded in Q3 2017.
- In the past 5 years, Soleno Therapeutics' Operating Income registered a high of -$559,783 during Q4 2013, and its lowest value of -$5.2 million during Q4 2017.
- Its 3-year average for Operating Income is -$2.9 million, with a median of -$2.8 million in 2017.
- In the last 5 years, Soleno Therapeutics' Operating Income slumped by 254.68% in 2015 and then surged by 67.79% in 2017.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Operating Income stood at -$559,783 in 2013, then crashed by 229.72% to -$1.8 million in 2014, then crashed by 89.99% to -$3.5 million in 2015, then spiked by 47.73% to -$1.8 million in 2016, then slumped by 183.62% to -$5.2 million in 2017.
- Its Operating Income was -$5.2 million in Q4 2017, compared to -$2.6 million in Q3 2017 and -$3.0 million in Q2 2017.